Novo Nordisk A/S (NYSE:NVO) Shares Bought by Princeton Global Asset Management LLC

Princeton Global Asset Management LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 56.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,781 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. Princeton Global Asset Management LLC’s holdings in Novo Nordisk A/S were worth $239,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. FSM Wealth Advisors LLC increased its position in Novo Nordisk A/S by 3.8% during the 4th quarter. FSM Wealth Advisors LLC now owns 5,394 shares of the company’s stock worth $448,000 after purchasing an additional 195 shares in the last quarter. Lynch Asset Management Inc. increased its position in Novo Nordisk A/S by 0.6% during the 4th quarter. Lynch Asset Management Inc. now owns 106,950 shares of the company’s stock worth $9,200,000 after purchasing an additional 650 shares in the last quarter. Stock Yards Bank & Trust Co. increased its position in Novo Nordisk A/S by 16.5% during the 4th quarter. Stock Yards Bank & Trust Co. now owns 4,604 shares of the company’s stock worth $396,000 after purchasing an additional 651 shares in the last quarter. Golden State Equity Partners increased its position in Novo Nordisk A/S by 327.4% during the 4th quarter. Golden State Equity Partners now owns 3,146 shares of the company’s stock worth $271,000 after purchasing an additional 2,410 shares in the last quarter. Finally, DAVENPORT & Co LLC increased its position in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after purchasing an additional 451,641 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $82.64 on Tuesday. The stock has a market cap of $370.85 billion, a P/E ratio of 26.74, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $93.56 and a 200-day moving average of $112.87. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.